HighVista Strategies LLC Has $1.38 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

HighVista Strategies LLC decreased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 6.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,128 shares of the company’s stock after selling 2,316 shares during the period. HighVista Strategies LLC owned 0.08% of Structure Therapeutics worth $1,379,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Sectoral Asset Management Inc. acquired a new stake in Structure Therapeutics during the 4th quarter valued at approximately $139,000. ADAR1 Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth $163,000. Sei Investments Co. bought a new position in Structure Therapeutics during the second quarter worth $212,000. Mather Group LLC. acquired a new position in Structure Therapeutics in the second quarter valued at $214,000. Finally, Gilbert & Cook Inc. bought a new stake in Structure Therapeutics during the second quarter valued at $229,000. 91.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on GPCR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 16th. JMP Securities dropped their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Finally, BMO Capital Markets increased their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and an average price target of $84.63.

Structure Therapeutics Trading Up 8.2 %

Shares of NASDAQ GPCR opened at $41.92 on Monday. The business has a 50-day moving average of $37.97 and a 200-day moving average of $39.61. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -54.44 and a beta of -3.52. Structure Therapeutics Inc. has a 12 month low of $26.61 and a 12 month high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. On average, analysts predict that Structure Therapeutics Inc. will post -0.86 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.